1. Home > Latest Topics >

Question 20: Cost-effectiveness data for levofloxacin in CAP

20 June, 2018

question_20_9


LATEST TOPICS

Navigating antibiotic resistance in community-acquired pneumonia: Insights from Vietnam
29 October, 2024
Optimising antibiotic therapy: Insights on transitioning from intravenous to oral treatment for community-acquired pneumonia
27 September, 2024
Community-acquired pneumonia in Cambodia: Navigating the growing challenge of AMR
30 June, 2024
Managing Infectious Diseases in Emergency Medicine: A Specialist’s Approach
10 April, 2024
Advancing standardised diagnosis and treatment of acute infectious disease: Insights from an expert in theory–technique integration
08 April, 2024

RELATED ARTICLES

Navigating antibiotic resistance in community-acquired pneumonia: Insights from Vietnam
29 October, 2024
Community-acquired pneumonia: Insights into the current challenges and the role of levofloxacin
29 January, 2024
Optimising the management of patients with community-acquired pneumonia and comorbidities with levofloxacin
05 December, 2022
Innovator versus Generic Antibiotics: Clinical Effectiveness in Pneumonia
23 October, 2023
Empiric Antibiotic Therapy for CAP in the Post-COVID-19 Era: Challenges and Insights
28 September, 2023